Amphastar Pharmaceuticals to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters

Reuters

2025/07/15

<a href="https://laohu8.com/S/AMPH">Amphastar Pharmaceuticals</a> to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters

Amphastar Pharmaceuticals Inc. has announced a significant expansion of its U.S. manufacturing operations at its Rancho Cucamonga headquarters. The bio-pharmaceutical company, known for its complex generic and proprietary injectable, inhalation, and intranasal products, plans to quadruple its production capacity over the next three to five years. This strategic initiative marks the largest investment in domestic infrastructure in Amphastar's history and aims to enhance supply chain resilience. The expansion will include a state-of-the-art production plant and advanced technologies, creating new jobs in research and development, engineering, manufacturing, and quality operations. Amphastar's commitment to domestic manufacturing is underscored by its focus on producing essential medicines in the United States.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1048521) on July 14, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2551359651"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551359651\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551359651?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-15 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551359651","market":"nz","top_or_hot":-1,"title":"Amphastar Pharmaceuticals to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AMPH\">Amphastar Pharmaceuticals</a> to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Amphastar Pharmaceuticals Inc. has announced a significant expansion of its U.S. manufacturing operations at its Rancho Cucamonga headquarters. The bio-pharmaceutical company, known for its complex generic and proprietary injectable, inhalation, and intranasal products, plans to quadruple its production capacity over the next three to five years. This strategic initiative marks the largest investment in domestic infrastructure in Amphastar's history and aims to enhance supply chain resilience. The expansion will include a state-of-the-art production plant and advanced technologies, creating new jobs in research and development, engineering, manufacturing, and quality operations. Amphastar's commitment to domestic manufacturing is underscored by its focus on producing essential medicines in the United States.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1048521) on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amphastar Pharmaceuticals to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmphastar Pharmaceuticals to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-15 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AMPH\">Amphastar Pharmaceuticals</a> to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Amphastar Pharmaceuticals Inc. has announced a significant expansion of its U.S. manufacturing operations at its Rancho Cucamonga headquarters. The bio-pharmaceutical company, known for its complex generic and proprietary injectable, inhalation, and intranasal products, plans to quadruple its production capacity over the next three to five years. This strategic initiative marks the largest investment in domestic infrastructure in Amphastar's history and aims to enhance supply chain resilience. The expansion will include a state-of-the-art production plant and advanced technologies, creating new jobs in research and development, engineering, manufacturing, and quality operations. Amphastar's commitment to domestic manufacturing is underscored by its focus on producing essential medicines in the United States.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1048521) on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL4gTzCf:1","article_id":"2551359651","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551359651","pubTimestamp":1752523522,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Amphastar Pharmaceuticals Inc. has announced a significant expansion of its U.S. manufacturing operations at its Rancho Cucamonga headquarters. The bio-pharmaceutical company, known for its complex generic and proprietary injectable, inhalation, and intranasal products, plans to quadruple its production capacity over the next three to five years. This strategic initiative marks the largest investment in domestic infrastructure in Amphastar's history and aims to enhance supply chain resilience. The expansion will include a state-of-the-art production plant and advanced technologies, creating new jobs in research and development, engineering, manufacturing, and quality operations. Amphastar's commitment to domestic manufacturing is underscored by its focus on producing essential medicines in the United States.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4585":"ETF&股票定投概念","AMPH":"Amphastar Pharmaceuticals","BK4588":"碎股","BK4557":"大麻股"},"translate_title":"Amphastar Pharmaceuticals将把库卡蒙加牧场总部的美国产能提高四倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMPH":0.9},"content_text":"Amphastar Pharmaceuticals to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters\n    \n\n        Amphastar Pharmaceuticals Inc. has announced a significant expansion of its U.S. manufacturing operations at its Rancho Cucamonga headquarters. The bio-pharmaceutical company, known for its complex generic and proprietary injectable, inhalation, and intranasal products, plans to quadruple its production capacity over the next three to five years. This strategic initiative marks the largest investment in domestic infrastructure in Amphastar's history and aims to enhance supply chain resilience. The expansion will include a state-of-the-art production plant and advanced technologies, creating new jobs in research and development, engineering, manufacturing, and quality operations. Amphastar's commitment to domestic manufacturing is underscored by its focus on producing essential medicines in the United States.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1048521) on July 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}